These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 32561465)

  • 1. Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia.
    Costanzo L; Palumbo FP; Ardita G; Antignani PL; Arosio E; Failla G;
    J Vasc Surg Venous Lymphat Disord; 2020 Sep; 8(5):711-716. PubMed ID: 32561465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.
    Tang N; Bai H; Chen X; Gong J; Li D; Sun Z
    J Thromb Haemost; 2020 May; 18(5):1094-1099. PubMed ID: 32220112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coagulopathy of Coronavirus Disease 2019.
    Iba T; Levy JH; Levi M; Connors JM; Thachil J
    Crit Care Med; 2020 Sep; 48(9):1358-1364. PubMed ID: 32467443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The coagulopathy, endotheliopathy, and vasculitis of COVID-19.
    Iba T; Connors JM; Levy JH
    Inflamm Res; 2020 Dec; 69(12):1181-1189. PubMed ID: 32918567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.
    Miesbach W; Makris M
    Clin Appl Thromb Hemost; 2020; 26():1076029620938149. PubMed ID: 32677459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulopathy and Plausible Benefits of Anticoagulation Among COVID-19 Patients.
    Ahmed SI; Khan S
    Curr Probl Cardiol; 2020 Sep; 45(9):100648. PubMed ID: 32703535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin as a therapy for COVID-19: current evidence and future possibilities.
    Hippensteel JA; LaRiviere WB; Colbert JF; Langouët-Astrié CJ; Schmidt EP
    Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L211-L217. PubMed ID: 32519894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET).
    Marietta M; Ageno W; Artoni A; De Candia E; Gresele P; Marchetti M; Marcucci R; Tripodi A
    Blood Transfus; 2020 May; 18(3):167-169. PubMed ID: 32281926
    [No Abstract]   [Full Text] [Related]  

  • 9. Research in brief: Coagulopathy in COVID-19: Determining and managing thrombotic risk in COVID-19 infection.
    Pooni RS
    Clin Med (Lond); 2020 Jul; 20(4):e59. PubMed ID: 32675158
    [No Abstract]   [Full Text] [Related]  

  • 10. [Coagulopathy and thrombosis: similarities and differences among pathogenic coronaviruses].
    Páramo JA
    An Sist Sanit Navar; 2020 Aug; 43(2):245-249. PubMed ID: 32814926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies.
    Allegra A; Innao V; Allegra AG; Musolino C
    Ann Hematol; 2020 Sep; 99(9):1953-1965. PubMed ID: 32671455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coagulopathy in COVID-19: Focus on vascular thrombotic events.
    Shi W; Lv J; Lin L
    J Mol Cell Cardiol; 2020 Sep; 146():32-40. PubMed ID: 32681845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis and Treatment Strategies of COVID-19-Related Hypercoagulant and Thrombotic Complications.
    Haimei MA
    Clin Appl Thromb Hemost; 2020; 26():1076029620944497. PubMed ID: 32722927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral Coagulopathy in Patients With COVID-19: Treatment and Care.
    Kipshidze N; Dangas G; White CJ; Kipshidze N; Siddiqui F; Lattimer CR; Carter CA; Fareed J
    Clin Appl Thromb Hemost; 2020; 26():1076029620936776. PubMed ID: 32687449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ISTH DIC subcommittee communication on anticoagulation in COVID-19.
    Thachil J; Juffermans NP; Ranucci M; Connors JM; Warkentin TE; Ortel TL; Levi M; Iba T; Levy JH
    J Thromb Haemost; 2020 Sep; 18(9):2138-2144. PubMed ID: 32881336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coagulation abnormalities and thrombosis in patients with COVID-19.
    Levi M; Thachil J; Iba T; Levy JH
    Lancet Haematol; 2020 Jun; 7(6):e438-e440. PubMed ID: 32407672
    [No Abstract]   [Full Text] [Related]  

  • 17. Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and Treatment.
    Aryal MR; Gosain R; Donato A; Pathak R; Bhatt VR; Katel A; Kouides P
    Curr Cardiol Rep; 2020 Jun; 22(7):52. PubMed ID: 32529517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk Benefit Analysis in Reference to use of LMWH in COVID-19.
    Samajdar SS; Sam PA; Moitra S; Ray Y; Pal J; Joshi SR; Tripathi SK
    J Assoc Physicians India; 2020 Sep; 68(9):52-61. PubMed ID: 32798346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19-Associated Coagulopathy: An Exacerbated Immunothrombosis Response.
    Jayarangaiah A; Kariyanna PT; Chen X; Jayarangaiah A; Kumar A
    Clin Appl Thromb Hemost; 2020; 26():1076029620943293. PubMed ID: 32735131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19.
    Conzelmann C; Müller JA; Perkhofer L; Sparrer KM; Zelikin AN; Münch J; Kleger A
    Clin Med (Lond); 2020 Nov; 20(6):e218-e221. PubMed ID: 32863274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.